Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo (an inactive substance with no therapeutic effect) and ketoconazole, an imidazole-class antifungal agent. Ketoconazole works by inhibiting the fungal enzyme lanosterol 14-α-demethylase, which is necessary for ergosterol synthesis in fungal cell membranes. This leads to increased membrane permeability and impaired cellular function, ultimately inhibiting fungal growth or killing the fungus. Placebo is used as a control in clinical trials and has no pharmacological activity. The combination may be used in research settings to compare the effects of ketoconazole against an inactive comparator.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + ketoconazole.